The Role of NPM1 in the Invasion and Migration of Drug Resistant Bladder Cancer
Vol. 18 No. 04 (2021),
Purpose: To study the difference of tumor progression caused by differential expression of NPM1 in drug-resistant bladder cancer.
Materials and Methods: The expression of NPM1 was analyzed by PCR and Western blot. NPM1 silencing bladder cancer cells (T24/DDP Lv-NPM1, PUMC-91/DDP Lv-NPM1) and overexpressing bladder cancer cells (T24/
DDP Lv5-NPM1, PUMC-91/DDP Lv5-NPM1) were established by lentivirus and limited dilution method. The
efficiency of gene interference was detected by fluorescence microscopy and Western blot. The migration ability and invasion ability of tumor in vitro were analyzed by wound healing assay and transwell cell invasion test, and the tumorigenic ability in vivo was judged by nude mouse tumorigenicity assay.
Results: Compared with the corresponding negative control group, both NPM1 silencing cell lines T24/DDP
Lv-NPM1 and PUMC-91/DDP Lv-NPM1 showed strong migration ability and high invasive ability. At the same
time, there was no significant difference in migration ability and the invasive cells proportion between NPM1
overexpressing cell line and related negative control group. NPM1 silencing bladder cancer cells had obvious
tumorigenicity in vivo.
Conclusion: NPM1 silencing cells had significant migration and invasion ability. The silencing of NPM1 will
accelerate tumorigenicity of drug resistant bladder cancer. Differential expression of NPM1 is of great value in
monitoring the progression of drug-resistant bladder cancer.
- bladder cancer
How to Cite
Bhanvadia SK. Bladder Cancer Survivorship. Current urology reports. 2018;19(12):111.
Martinez Rodriguez RH, Buisan Rueda O, Ibarz L. Bladder cancer: Present and future. Medicina clinica. 2017;149(10):449-455.
Duff D, Long A. Roles for RACK1 in cancer cell migration and invasion. Cellular signalling. 2017;35:250-255.
Kim JY, Cho YE, An YM, et al. GLTSCR2 is an upstream negative regulator of nucleophosmin in cervical cancer. Journal of cellular and molecular medicine. 2015;19(6):1245-1252.
Endo A, Matsumoto M, Inada T, et al. Nucleolar structure and function are regulated by the deubiquitylating enzyme USP36. Journal of cell science. 2009;122(Pt 5):678-686.
Liu Y, Zhang F, Zhang XF, et al. Expression of nucleophosmin/NPM1 correlates with migration and invasiveness of colon cancer cells. Journal of biomedical science. 2012;19:53.
He J, Xiang Z, Xiao J, Xiao H, Liu L. [The poor chemotherapeutic efficacy in lung adenocarcinoma overexpressing c-Src and nucleophosmin/B23(NPM1)]. Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology. 2016;32(10):1378-1381.
Forghieri F, Riva G, Lagreca I, et al. Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia. Oncotarget. 2019;10(8):869-882.
Li S, Zhang X, Zhou Z, Huang Z, Liu L, Huang Z. Downregulation of nucleophosmin expression inhibited proliferation and induced apoptosis in salivary gland adenoid cystic carcinoma. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology. 2017;46(3):175-181.
Heath EM, Chan SM, Minden MD, Murphy T, Shlush LI, Schimmer AD. Biological and clinical consequences of NPM1 mutations in AML. Leukemia. 2017;31(4):798-807.
Lei T, Zhao X, Jin S, Meng Q, Zhou H, Zhang M. Discovery of potential bladder cancer biomarkers by comparative urine proteomics and analysis. Clinical genitourinary cancer. 2013;11(1):56-62.
Hu H, Meng Q, Lei T, Zhang M. Nucleophosmin1 associated with drug resistance and recurrence of bladder cancer. Clinical and experimental medicine. 2015;15(3):361-369.
Li TT, Li J, Geng YH, Zhang F, Liu L, Yang YL. [NRAS Gene Expression and Its Clinical Significance in Patients with Acute Myeloid Leukemia]. Zhongguo shi yan xue ye xue za zhi. 2020;28(1):76-81.
Jain P, Kantarjian H, Patel K, et al. Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. Leukemia & lymphoma. 2014;55(6):1337-1344.
Kurki S, Peltonen K, Latonen L, et al. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer cell. 2004;5(5):465-475.
Jin A, Itahana K, O'Keefe K, Zhang Y. Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Molecular and cellular biology. 2004;24(17):7669-7680.
Bertoli S, Tavitian S, Berard E, et al. More than ten percent of relapses occur after five years in AML patients with NPM1 mutation. Leukemia & lymphoma. 2020:1-4.
Chen S, Li X, Ma S, Xing X, Wang X, Zhu Z. Chemogenomics analysis of drug targets for the treatment of acute promyelocytic leukemia. Annals of hematology. 2020.
Jian Y, Gao Z, Sun J, et al. RNA aptamers interfering with nucleophosmin oligomerization induce apoptosis of cancer cells. Oncogene. 2009;28(47):4201-4211.
Wang W, Budhu A, Forgues M, Wang XW. Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication. Nature cell biology. 2005;7(8):823-830.
Coutinho-Camillo CM, Lourenco SV, Nishimoto IN, Kowalski LP, Soares FA. Nucleophosmin, p53, and Ki-67 expression patterns on an oral squamous cell carcinoma tissue microarray. Human pathology. 2010;41(8):1079-1086.
Leal MF, Mazzotti TK, Calcagno DQ, et al. Deregulated expression of Nucleophosmin 1 in gastric cancer and its clinicopathological implications. BMC gastroenterology. 2014;14:9.
Chang S, Yim S, Park H. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism. Experimental & molecular medicine. 2019;51(6):66.
Trop-Steinberg S, Azar Y. Is Myc an Important Biomarker? Myc Expression in Immune Disorders and Cancer. The American journal of the medical sciences. 2018;355(1):67-75.
Bonetti P, Davoli T, Sironi C, Amati B, Pelicci PG, Colombo E. Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7 gamma. The Journal of cell biology. 2008;182(1):19-26.
Chen JB, Zhang M, Zhang XL, et al. Glucocorticoid-Inducible Kinase 2 Promotes Bladder Cancer Cell Proliferation, Migration and Invasion by Enhancing beta-catenin/c-Myc Signaling Pathway. Journal of Cancer. 2018;9(24):4774-4782.
Cheng M, Sheng L, Gao Q, et al. The m(6)A methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-kappaB/MYC signaling network. Oncogene. 2019;38(19):3667-3680.
- Abstract Viewed: 0 times
- 6087/pdf Downloaded: 0 times